share_log

DexCom | 8-K: Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

DexCom | 8-K: Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

德康医疗 | 8-K：Dexcom公布2024年第二季度财务业绩，更新指导方针，并宣布7.5亿美元股票回购计划
美股SEC公告 ·  2024/07/26 04:09

Moomoo AI 已提取核心信息

DexCom reported Q2 2024 revenue of $1.004B, up 15% YoY. U.S. revenue grew 19% to $731.9M, while international revenue rose 7% to $272.4M. GAAP operating income was $158.0M, or 15.7% of revenue.The company updated its FY 2024 guidance, now expecting revenue of $4.00-4.05B (11-13% organic growth) and non-GAAP gross profit margin of ~63%. It maintained non-GAAP operating margin guidance of ~20% and adjusted EBITDA margin of ~29%. For Q3 2024, DexCom projects revenue of $975M-$1.00B.DexCom also announced a $750M share repurchase program. Key Q2 highlights include launching Direct-to-Watch in the U.S. and internationally, securing coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin, and advancing pump connectivity with Insulet and Tandem Diabetes Care.
DexCom reported Q2 2024 revenue of $1.004B, up 15% YoY. U.S. revenue grew 19% to $731.9M, while international revenue rose 7% to $272.4M. GAAP operating income was $158.0M, or 15.7% of revenue.The company updated its FY 2024 guidance, now expecting revenue of $4.00-4.05B (11-13% organic growth) and non-GAAP gross profit margin of ~63%. It maintained non-GAAP operating margin guidance of ~20% and adjusted EBITDA margin of ~29%. For Q3 2024, DexCom projects revenue of $975M-$1.00B.DexCom also announced a $750M share repurchase program. Key Q2 highlights include launching Direct-to-Watch in the U.S. and internationally, securing coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin, and advancing pump connectivity with Insulet and Tandem Diabetes Care.
德康医疗报告称2024年第二季度营业收入为10.04亿，同比增长15%。美国营业收入增长19%，达到73190万，而国际营业收入增长7%，达到27240万。根据公认会计原则，营业收入为15800万，占营业收入的15.7%。该公司更新了2024财年的指引，现在预计营业收入为40-40.5亿（有机增长11-13%）和非公认会计原则下的毛利润率约为63%。它维持非公认会计原则下的营业利润率指引约为20%及调整后的息税折旧及摊销前利润率约为29%。对于2024年第三季度，德康医疗预计营业收入为97500万。$10亿。德康医疗还宣布了一项75000万的股票回购计划。第二季度的主要亮点包括在美国和国际上推出了直达手表（Direct-to-Watch），为使用基础胰岛素的2型糖尿病患者在法国获得了Dexcom ONE的保险覆盖，并与银休特及Tandem Diabetes Care推动泵的连接。
德康医疗报告称2024年第二季度营业收入为10.04亿，同比增长15%。美国营业收入增长19%，达到73190万，而国际营业收入增长7%，达到27240万。根据公认会计原则，营业收入为15800万，占营业收入的15.7%。该公司更新了2024财年的指引，现在预计营业收入为40-40.5亿（有机增长11-13%）和非公认会计原则下的毛利润率约为63%。它维持非公认会计原则下的营业利润率指引约为20%及调整后的息税折旧及摊销前利润率约为29%。对于2024年第三季度，德康医疗预计营业收入为97500万。$10亿。德康医疗还宣布了一项75000万的股票回购计划。第二季度的主要亮点包括在美国和国际上推出了直达手表（Direct-to-Watch），为使用基础胰岛素的2型糖尿病患者在法国获得了Dexcom ONE的保险覆盖，并与银休特及Tandem Diabetes Care推动泵的连接。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    古特拉
    CUTR
    -- 0.484
    Outset Medical
    OM
    -- 1.400
    Lifeward
    LFWD
    -- 2.660
    Catheter Precision
    VTAK
    -- 0.530
    Baird Medical Investment Holdings
    BDMD
    -- 6.040

    解锁榜首股票